Subcutaneous Biologics Market (5th Edition), Industry Trends and Global Forecasts, till 2035 – Distribution by Type of Biologic, Type of Therapy, Method of Administration, Fundamental Principle, End User, Payment Method Employed, Therapeutic Area, Drug D
Description
Subcutaneous Biologics Market: Overview
As per Roots Analysis, the global subcutaneous biologics market is estimated to grow from USD 251 billion in the current year to USD 233 billion by 2035.
The market sizing and opportunity analysis has been segmented across the following parameters:
Type of Biologic
The demand of biologics has risen in the recent years in the pharmaceutical industry. In fact, the industry has witnessed a rise in the number of biologic drugs approved by the USFDA. This shift is due to the ability of biologics to offer targeted treatment, enabling minimal drug interactions owing to their precise binding and unique metabolic pathways.
However, developing biologics involves various challenges. These include high molecular weight, structure complexity susceptibility to degradation after administration, and productional complexities have prompted pharmaceutical companies to adopt new technologies for their development. Formulating subcutaneous biologics via conjugation, amino acid modification, and encapsulation methods are some of these technological innovations.
Additionally, novel drug delivery systems, including autoinjectors, pre-filled syringes, and needle-free methods, have been developed to administer highly viscous formulations. Previously, biologics were administered intravenously because of their swift systemic distribution and strong bioavailability. Although intravenous administration is effective, it frequently necessitates regular administration by healthcare providers, creating a hurdle for medication adherence. In recent years, methods and devices for subcutaneous administration have become increasingly popular among healthcare practitioners due to their effectiveness, safety, and tolerability Moreover, the shift towards subcutaneous biologics is fueled by the increasing need for self-administered treatments and the presence of easy-to-use drug delivery tools such as autoinjectors and pre-filled syringes.
Subcutaneous Biologics Market: Key Insights
The report delves into the current state of the subcutaneous biologics market and identifies potential growth opportunities within industry. Some key findings from the report include:
Approved Subcutaneous Biologics Market
Antibodies Occupy the Highest Share in the Market
Based on type of biologic, the global market for approved subcutaneous biologics is segmented into antibodies, nucleotides and proteins. It is worth mentioning that, currently, antibodies occupy the highest share in the market, attributing to its higher target specificity, increased safety profile and lower toxicity. Further, approved subcutaneous biologics market for nucleotides is expected to witness substantial growth during the forecast period.
The Highest Market Share is Captured by Both Monotherapy and Combination Therapies
The global market for approved subcutaneous biologics is segmented across monotherapy, combination therapy, and both monotherapy and combination therapies. Both monotherapy and combination therapies segments occupy the largest current market share and is expected to witness a substantial growth during the forecast period.
Majority of the Approved Subcutaneous Biologics Market Share is Occupied by Injection
This segment highlights the distribution of global market for approved subcutaneous biologics across different types of methods of administration, such as injection, infusion, and both injection and infusion. It is worth highlighting that, presently, majority of the approved subcutaneous biologics market share is occupied by injection as a method of administration and is expected to remain dominant, during the forecast period. This can be attributed to the fact that delivery via injections is more convenient for the patients as well as healthcare professionals. Additionally, the chances of any allergic reaction and fluid overload are also reduced.
Autoimmune Disorders Segment Occupies the Highest Subcutaneous Biologics Market Share
Based on therapeutic area, the global market for approved subcutaneous biologics is segmented into autoimmune disorders, metabolic disorders, oncological disorders, hematological disorders, inflammatory disorders, neurological disorders, bone disorders and other disorders. Currently, autoimmune disorders segment occupies the highest subcutaneous biologics market share. This can be primarily attributed to the high efficacy of these drugs in the treatment of various prevalent autoimmune disorders, such as psoriasis, ankylosing spondylitis, ulcerative colitis and Crohn's disease. However, during the forecast period, metabolic disorders segment is likely to capture a larger market share owing to the rising preference of subcutaneous injection for the administration in patients suffering from diabetes mellitus and obesity (wherein long-term administration of drugs is required).
North America is Likely to Capture a Majority Share in the Overall Market
This segment highlights the distribution of approved subcutaneous biologics market across various geographies, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our projections, presently, North America is likely to capture a majority share (~50%) in the overall market. Further, it is worth highlighting that the market in Asia-Pacific is expected to grow at a relatively higher CAGR, during the forecast period, till 2035. The growth of the market in Asia-Pacific can be ascribed to the rapidly growing patient population, the rising incidence of chronic disorders (including neurological disorders, genetic disorders and autoimmune disorders), and the rising demand for effective and advanced therapeutics. Further, the increasing investments and initiatives taken by regulatory bodies in the Asian countries to promote the adoption of biologics among patients and physicians is likely to drive the market in future.
Subcutaneous Biologics Market for Formulation Technologies
Market Share by Fundamental Principle
The global subcutaneous biologics formulation technology market is segmented across various fundamental principles, such as amino acid interaction, complex formation, conjugation, amino acid interaction, encapsulation and other fundamental principles. Presently, the revenues generated through the licensing of technologies that are based on encapsulation principle are likely to capture majority share in the overall market and is expected to remain dominant during the forecast period. It is worth highlighting that encapsulation helps in increasing the solubility of the biologics that are hydrophobic, which further results in increased absorption of the drugs in the patient’s body. Further, drug encapsulation also leads to high target specificity, thereby reducing the likelihood of adverse effects (that usually occur due to high systemic exposure).
Biotechnology Companies are Estimated to Grow at a Relatively Higher CAGR
The global subcutaneous biologics formulation technology market caters to a wide variety of end users, including biotechnology companies, contract development and manufacturing organizations, educational institutes, medical equipment manufacturers, MedTech companies, pharmaceutical and biopharmaceutical companies and other end users. Notably, pharmaceutical and biopharmaceutical companies are expected to currently capture the highest share in the market, However, biotechnology companies are estimated to grow at a relatively higher CAGR, during the forecast period.
Oncological Disorders Hold the Largest Share in the Subcutaneous Technology Market
This segment highlights the distribution of global subcutaneous biologics formulation technology market across different therapeutic areas, such as autoimmune disorders, bone diseases, hematological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, ocular disorders, oncological disorders and other disorders. It is worth highlighting that the oncological disorders hold the largest share in the current technology market. This can be attributed to the high incidence rate of oncological disorders, accounting for around 1.9 million cases in 2022 and over 2 million cases in 2023. Further, the global subcutaneous biologics market for formulation technology for autoimmune disorders is estimated to grow at the highest CAGR, during the forecast period.
Subcutaneous Biologics Formulation Technology Market in Asia-Pacific is Expected To Grow with the Highest CAGR
This segment highlights the distribution of subcutaneous biologics formulation technology market across various geographies, such as North America, Europe and Asia-Pacific. It is worth highlighting that North America captures close to 65% of the current global subcutaneous biologics market for formulation technology. Further, the subcutaneous biologics formulation technology market in Asia-Pacific is expected to grow with the highest CAGR, during the forecast period. The growth of market in Asia-Pacific can be attributed to the rise in number of technology developers in this region, that will be actively involved in inking licensing deals with the drug developers.
Milestone Payments Occupy the Majority Share
Based on payment method employed, the global subcutaneous formulation technology market is segmented into milestone payments and upfront payments. It is worth mentioning that milestone payments occupy the majority share in the current market and this trend is unlikely to change in the future.
Example Players in the Subcutaneous Biologics Market
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
As per Roots Analysis, the global subcutaneous biologics market is estimated to grow from USD 251 billion in the current year to USD 233 billion by 2035.
The market sizing and opportunity analysis has been segmented across the following parameters:
Type of Biologic
- Antibodies
- Nucleotides
- Proteins
- Monotherapies
- Combination Therapies
- Both (Monotherapies and Combination Therapies)
- Injection
- Infusion
- Both (Injection and Infusion)
- Encapsulation
- Complex Formation
- Conjugation
- Amino acid Interaction
- Other Fundamental Principles
- Pharmaceutical and Biopharmaceutical Companies
- Biotechnology Companies
- MedTech Companies
- Contract Development and Manufacturing Organizations
- Educational Institutes
- Medical Equipment Manufacturers
- Other End Users
- Milestone Payments
- Upfront Payments
- Autoimmune Disorders
- Bone Disorders
- Hematological Disorders
- Infectious Diseases
- Inflammatory Disorders
- Metabolic Disorders
- Neurological Disorders
- Ocular Disorders
- Oncological Disorders
- Other Disorders
- Large Volume Wearable Injectors
- Autoinjectors
- Needle-free Injection System
- Novel Drug Reconstitution System
- Prefilled Syringes
- North America
- Europe
- Asia-Pacific
- Middle East and North Africa
- Latin America
The demand of biologics has risen in the recent years in the pharmaceutical industry. In fact, the industry has witnessed a rise in the number of biologic drugs approved by the USFDA. This shift is due to the ability of biologics to offer targeted treatment, enabling minimal drug interactions owing to their precise binding and unique metabolic pathways.
However, developing biologics involves various challenges. These include high molecular weight, structure complexity susceptibility to degradation after administration, and productional complexities have prompted pharmaceutical companies to adopt new technologies for their development. Formulating subcutaneous biologics via conjugation, amino acid modification, and encapsulation methods are some of these technological innovations.
Additionally, novel drug delivery systems, including autoinjectors, pre-filled syringes, and needle-free methods, have been developed to administer highly viscous formulations. Previously, biologics were administered intravenously because of their swift systemic distribution and strong bioavailability. Although intravenous administration is effective, it frequently necessitates regular administration by healthcare providers, creating a hurdle for medication adherence. In recent years, methods and devices for subcutaneous administration have become increasingly popular among healthcare practitioners due to their effectiveness, safety, and tolerability Moreover, the shift towards subcutaneous biologics is fueled by the increasing need for self-administered treatments and the presence of easy-to-use drug delivery tools such as autoinjectors and pre-filled syringes.
Subcutaneous Biologics Market: Key Insights
The report delves into the current state of the subcutaneous biologics market and identifies potential growth opportunities within industry. Some key findings from the report include:
- Presently, more than 175 subcutaneous biologics have been approved for the treatment of various chronic disorders; around 50% of these biologics are proteins approved for once daily administration.
- ~20% of the subcutaneous biologics have been approved post-2020, majority of which are antibodies that can be administered as monotherapy alone.
- More than 340 subcutaneous biologics are in clinical-stages of development; ~10% of these biologics are antibodies that have received orphan drug designation.
- Around 60% of the clinical-stage subcutaneous biologics are based on inhibition mechanism; interestingly, majority of these biologics can be administered as monotherapy alone.
- Close to 20% of technologies are based on encapsulation principle; notably, all these technologies are focused towards providing extended / controlled / sustained drug release
- The rising interest in this domain is reflected by the rise in partnership activity; in fact, close to 70% of the deals were inked in the last three years.
- There are several new and innovative drug delivery systems that facilitate subcutaneous administration; we identified over 560 such systems that are presently available / under development.
- Driven by the increased emphasis towards patient compliance and improved treatment outcome, the approved subcutaneous biologics market is likely to grow at a CAGR of ~5%, till 2027.
- Owing to the numerous advantages offered by subcutaneous formulation technologies and increase in the number of licensing deals, the market is anticipated to grow at an annualized rate of 22.7% in the coming decade.
Approved Subcutaneous Biologics Market
Antibodies Occupy the Highest Share in the Market
Based on type of biologic, the global market for approved subcutaneous biologics is segmented into antibodies, nucleotides and proteins. It is worth mentioning that, currently, antibodies occupy the highest share in the market, attributing to its higher target specificity, increased safety profile and lower toxicity. Further, approved subcutaneous biologics market for nucleotides is expected to witness substantial growth during the forecast period.
The Highest Market Share is Captured by Both Monotherapy and Combination Therapies
The global market for approved subcutaneous biologics is segmented across monotherapy, combination therapy, and both monotherapy and combination therapies. Both monotherapy and combination therapies segments occupy the largest current market share and is expected to witness a substantial growth during the forecast period.
Majority of the Approved Subcutaneous Biologics Market Share is Occupied by Injection
This segment highlights the distribution of global market for approved subcutaneous biologics across different types of methods of administration, such as injection, infusion, and both injection and infusion. It is worth highlighting that, presently, majority of the approved subcutaneous biologics market share is occupied by injection as a method of administration and is expected to remain dominant, during the forecast period. This can be attributed to the fact that delivery via injections is more convenient for the patients as well as healthcare professionals. Additionally, the chances of any allergic reaction and fluid overload are also reduced.
Autoimmune Disorders Segment Occupies the Highest Subcutaneous Biologics Market Share
Based on therapeutic area, the global market for approved subcutaneous biologics is segmented into autoimmune disorders, metabolic disorders, oncological disorders, hematological disorders, inflammatory disorders, neurological disorders, bone disorders and other disorders. Currently, autoimmune disorders segment occupies the highest subcutaneous biologics market share. This can be primarily attributed to the high efficacy of these drugs in the treatment of various prevalent autoimmune disorders, such as psoriasis, ankylosing spondylitis, ulcerative colitis and Crohn's disease. However, during the forecast period, metabolic disorders segment is likely to capture a larger market share owing to the rising preference of subcutaneous injection for the administration in patients suffering from diabetes mellitus and obesity (wherein long-term administration of drugs is required).
North America is Likely to Capture a Majority Share in the Overall Market
This segment highlights the distribution of approved subcutaneous biologics market across various geographies, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our projections, presently, North America is likely to capture a majority share (~50%) in the overall market. Further, it is worth highlighting that the market in Asia-Pacific is expected to grow at a relatively higher CAGR, during the forecast period, till 2035. The growth of the market in Asia-Pacific can be ascribed to the rapidly growing patient population, the rising incidence of chronic disorders (including neurological disorders, genetic disorders and autoimmune disorders), and the rising demand for effective and advanced therapeutics. Further, the increasing investments and initiatives taken by regulatory bodies in the Asian countries to promote the adoption of biologics among patients and physicians is likely to drive the market in future.
Subcutaneous Biologics Market for Formulation Technologies
Market Share by Fundamental Principle
The global subcutaneous biologics formulation technology market is segmented across various fundamental principles, such as amino acid interaction, complex formation, conjugation, amino acid interaction, encapsulation and other fundamental principles. Presently, the revenues generated through the licensing of technologies that are based on encapsulation principle are likely to capture majority share in the overall market and is expected to remain dominant during the forecast period. It is worth highlighting that encapsulation helps in increasing the solubility of the biologics that are hydrophobic, which further results in increased absorption of the drugs in the patient’s body. Further, drug encapsulation also leads to high target specificity, thereby reducing the likelihood of adverse effects (that usually occur due to high systemic exposure).
Biotechnology Companies are Estimated to Grow at a Relatively Higher CAGR
The global subcutaneous biologics formulation technology market caters to a wide variety of end users, including biotechnology companies, contract development and manufacturing organizations, educational institutes, medical equipment manufacturers, MedTech companies, pharmaceutical and biopharmaceutical companies and other end users. Notably, pharmaceutical and biopharmaceutical companies are expected to currently capture the highest share in the market, However, biotechnology companies are estimated to grow at a relatively higher CAGR, during the forecast period.
Oncological Disorders Hold the Largest Share in the Subcutaneous Technology Market
This segment highlights the distribution of global subcutaneous biologics formulation technology market across different therapeutic areas, such as autoimmune disorders, bone diseases, hematological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, ocular disorders, oncological disorders and other disorders. It is worth highlighting that the oncological disorders hold the largest share in the current technology market. This can be attributed to the high incidence rate of oncological disorders, accounting for around 1.9 million cases in 2022 and over 2 million cases in 2023. Further, the global subcutaneous biologics market for formulation technology for autoimmune disorders is estimated to grow at the highest CAGR, during the forecast period.
Subcutaneous Biologics Formulation Technology Market in Asia-Pacific is Expected To Grow with the Highest CAGR
This segment highlights the distribution of subcutaneous biologics formulation technology market across various geographies, such as North America, Europe and Asia-Pacific. It is worth highlighting that North America captures close to 65% of the current global subcutaneous biologics market for formulation technology. Further, the subcutaneous biologics formulation technology market in Asia-Pacific is expected to grow with the highest CAGR, during the forecast period. The growth of market in Asia-Pacific can be attributed to the rise in number of technology developers in this region, that will be actively involved in inking licensing deals with the drug developers.
Milestone Payments Occupy the Majority Share
Based on payment method employed, the global subcutaneous formulation technology market is segmented into milestone payments and upfront payments. It is worth mentioning that milestone payments occupy the majority share in the current market and this trend is unlikely to change in the future.
Example Players in the Subcutaneous Biologics Market
- Adocia
- Alteogen
- Ascendis Pharma
- CD Bioparticles
- Creative Biolabs
- Creative BioMart
- Foresee Pharmaceuticals
- Pacira Biosciences
- The Wyss Institute
- Xeris Biopharma
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
- Founder and Chief Executive Officer, Small Company, US
- Founder and Chief Technology Officer, Mid-sized Company, UK
- Chief Executive Officer & Founder, Small Company, US
- Chief Executive Officer, Small Company, Denmark
- Chief Executive Officer, Mid-sized Company, US
- Chief Technical Officer, Very Large Company, India
- Vice President and Chief Scientist, Large Company, Israel
- Senior Portfolio Director, Large Company, US
- Managing Director, Small Company, Austria
- Communication Leader, Mid-sized Company, France
- Former Founder and Chief Scientific Officer, Vice President and Product Development, Former Senior Scientist Formulation, Mid-sized Company, US
- Former Chief Commercial Officer, Large Company, Germany
- Anonymous, a US-based company
- Anonymous, a Europe-based company
- Market Sizing and Opportunity Analysis: The report features a thorough analysis of the global subcutaneous biologics market, in terms of the key market segments, including [A] type of primary packaging container, [B] type of biologic, [C] type of therapy, [D] method of administration, [E] fundamental principle, [F] end-user, [G] payment method employed, and [H] therapeutic area, [I] type of drug delivery device and [J] geographical regions.
- Market Landscape: An in-depth assessment of the companies involved in the subcutaneous biologics market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] status of development, [E]type of biologic, [F] type of therapy, [G] mechanism of action, [H] dosing frequency, [I] target disease indication, [J] therapeutic area and [K] drug designation.
- Technology Landscape: An in-depth assessment of the landscape of subcutaneous formulation technologies in the subcutaneous biologics market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] as fundamental principle, [E] type of molecule, [F] route of administration, [G] therapeutic area and [H] key characteristics.
- Technology Competitive Analysis: A comprehensive analysis of subcutaneous formulation technologies based on parameters, such as [A] company strength and [B] technology strength.
- Company Profiles: In-depth profiles of leading subcutaneous formulation technology developers based in North America, Europe and Asia-Pacific engaged in the subcutaneous market, focused on parameters such as [A] company overview, [B] financial information (if available), [C] service portfolio, [D] manufacturing facilities and [E] recent developments and an informed future outlook.
- Partnerships and Collaborations: An in-depth analysis of the partnership’s activity reported in this domain, based on parameters such as [A] year of partnership, [B] type of partnership [C] type of partner company.
- SWOT Analysis: Deep insights on industry affiliated trends, opportunities and challenges, under SWOT analysis, which are anticipated to impact the overall evolution of the subcutaneous biologics market.
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
- Complimentary PPT Insights Packs
Key Questions Answered in this Report
Table of Contents
997 Pages
- 1. Preface
- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
- 2. Research Methodology
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.2.1. Market Landscape And Market Trends
- 2.2.2. Market Forecast And Opportunity Analysis
- 2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
- 2.4. Project Methodology
- 2.4.1. Secondary Research
- 2.4.1.1. Annual Reports
- 2.4.1.2. Academic Research Papers
- 2.4.1.3. Company Websites
- 2.4.1.4. Investor Presentations
- 2.4.1.5. Regulatory Filings
- 2.4.1.6. White Papers
- 2.4.1.7. Industry Publications
- 2.4.1.8. Conferences And Seminars
- 2.4.1.9. Government Portals
- 2.4.1.10. Media And Press Releases
- 2.4.1.11. Newsletters
- 2.4.1.12. Industry Databases
- 2.4.1.13. Roots Proprietary Databases
- 2.4.1.14. Paid Databases And Sources
- 2.4.1.15. Social Media Portals
- 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
- 2.4.2.1. Types Of Primary Research
- 2.4.2.1.1. Qualitative Research
- 2.4.2.1.2. Quantitative Research
- 2.4.2.1.3. Hybrid Approach
- 2.4.2.2. Advantages Of Primary Research
- 2.4.2.3. Techniques For Primary Research
- 2.4.2.3.1. Interviews
- 2.4.2.3.2. Surveys
- 2.4.2.3.3. Focus Groups
- 2.4.2.3.4. Observational Research
- 2.4.2.3.5. Social Media Interactions
- 2.4.2.4. Key Opinion Leaders Considered In Primary Research
- 2.4.2.4.1. Company Executives (Cxos)
- 2.4.2.4.2. Board Of Directors
- 2.4.2.4.3. Company Presidents And Vice Presidents
- 2.4.2.4.4. Research And Development Heads
- 2.4.2.4.5. Technical Experts
- 2.4.2.4.6. Subject Matter Experts
- 2.4.2.4.7. Scientists
- 2.4.2.4.8. Doctors And Other Healthcare Providers
- 2.4.2.5. Ethics And Integrity
- 2.4.2.5.1. Research Ethics
- 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools And Databases
- 3. Market Dynamics
- 3.1. Chapter Overview
- 3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
- 3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (Tam)
- 3.3.2. Serviceable Addressable Market (Sam)
- 3.3.3. Serviceable Obtainable Market (Som)
- 3.3.4. Currently Acquired Market (Cam)
- 3.4. Forecasting Tools And Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
- 3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
- 3.6. Key Market Segmentation
- 3.7. Robust Quality Control
- 3.8. Limitations
- 4. Economic And Other Project Specific Considerations
- 4.1. Chapter Overview
- 4.2. Market Dynamics
- 4.2.1. Time Period
- 4.2.1.1. Historical Trends
- 4.2.1.2. Current And Future Estimates
- 4.2.2. Currency Coverage And Foreign Exchange Rate
- 4.2.2.1. Major Currencies Affecting The Market
- 4.2.2.2. Factors Affecting Currency Fluctuations And Foreign Exchange Rates
- 4.2.2.3. Impact Of Foreign Exchange Rate Volatility On The Market
- 4.2.2.4. Strategies For Mitigating Foreign Exchange Risk
- 4.2.3. Trade Policies
- 4.2.3.1. Impact Of Trade Barriers On The Market
- 4.2.3.2. Strategies For Mitigating The Risks Associated With Trade Barriers
- 4.2.4. Recession
- 4.2.4.1. Historical Analysis Of Past Recessions And Lessons Learnt
- 4.2.4.2. Assessment Of Current Economic Conditions And Potential Impact On The Market
- 4.2.5. Inflation
- 4.2.5.1. Measurement And Analysis Of Inflationary Pressures In The Economy
- 4.2.5.2. Potential Impact Of Inflation On The Market Evolution
- 5. Executive Summary
- 6. Introduction
- 6.1. Chapter Overview
- 6.2. Types Of Therapeutic Molecules
- 6.3. Biologically Derived Molecules
- 6.3.1. Type Of Products
- 6.3.2. Routes Of Administration And Formulations
- 6.3.3. Subcutaneous Formulations
- 6.3.3.1. Approaches In Subcutaneous Delivery Of Biologics
- 6.3.3.1.1. Reformulation
- 6.3.3.1.2. Differing Potencies
- 6.3.3.1.3. Novel Technologies
- 6.3.3.2. Methods Of Subcutaneous Administration
- 6.3.3.3. Advantages Of Subcutaneous Administration
- 6.3.3.4. Limitations Of Subcutaneous Administration
- 6.4. Regulatory Considerations
- 6.4.1. Medical Devices
- 6.4.2. Drug Device Combination Products
- 6.5. Future Perspectives
- 7. Approved Subcutaneous Biologics: Market Landscape
- 7.1. Chapter Overview
- 7.2. Approved Subcutaneous Biologics: Overall Market Overview
- 7.2.1. Analysis By Initial Approval Year
- 7.2.2. Analysis By Type Of Biologic
- 7.2.3. Analysis By Type Of Therapy
- 7.2.4. Analysis By Route Of Administration
- 7.2.5. Analysis By Method Of Administration
- 7.2.6. Analysis By Dosing Frequency
- 7.2.7. Analysis By Concentration Of Dose
- 7.2.8. Analysis By Target Disease Indication
- 7.2.9. Analysis By Therapeutic Area
- 7.2.10. Analysis By Type Of Drug Delivery Device
- 7.3. Approved Subcutaneous Biologics: List Of Developers
- 7.3.1. Analysis By Year Of Establishment
- 7.3.2. Analysis By Company Size
- 7.3.3. Analysis By Location Of Headquarters (Region)
- 7.3.4. Analysis By Location Of Headquarters (Country)
- 7.3.5. Most Active Developers: Analysis By Number Of Approved Drugs
- 8. Approved Subcutaneous Biologics: Success Protocol Analysis
- 8.1. Chapter Overview
- 8.2. Methodology
- 8.3. Success Protocol Analysis Of Top Approved Subcutaneous Biologics
- 8.3.1. Benlysta® (Human Genome Sciences)
- 8.3.1.1. Overview
- 8.3.1.2. Development History
- 8.3.1.3. Phase Of Development, Route Of Administration, And Target Disease Indication
- 8.3.1.4. Success Protocol Analysis
- 8.3.2. Besremi® (Pharmaessentia)
- 8.3.2.1. Overview
- 8.3.2.2. Development History
- 8.3.2.3. Phase Of Development, Route Of Administration, And Target Disease Indication
- 8.3.2.4. Success Protocol Analysis
- 8.3.3. Cosentyx® (Novartis)
- 8.3.3.1. Overview
- 8.3.3.2. Development History
- 8.3.3.3. Phase Of Development, Route Of Administration, And Target Disease Indication
- 8.3.3.4. Success Protocol Analysis
- 8.3.4. Darzalex Faspro® / Darzalex® Sc (Halozyme)
- 8.3.4.1. Overview
- 8.3.4.2. Development History
- 8.3.4.3. Phase Of Development, Route Of Administration, And Target Disease Indication
- 8.3.4.4. Success Protocol Analysis
- 8.3.5. Dupixent® (Regeneron Pharma)
- 8.3.5.1. Overview
- 8.3.5.2. Development History
- 8.3.5.3. Phase Of Development, Route Of Administration, And Target Disease Indication
- 8.3.5.4. Success Protocol Analysis
- 8.3.6. Enbrel® (Amgen)
- 8.3.6.1. Overview
- 8.3.6.2. Development History
- 8.3.6.3. Phase Of Development, Route Of Administration, And Target Disease Indication
- 8.3.6.4. Success Protocol Analysis
- 8.3.7. Hemlibra® (Roche)
- 8.3.7.1. Overview
- 8.3.7.2. Development History
- 8.3.7.3. Phase Of Development, Route Of Administration, And Target Disease Indication
- 8.3.7.4. Success Protocol Analysis
- 8.3.8. Prolia® / Pralia® (Amgen)
- 8.3.8.1. Overview
- 8.3.8.2. Development History
- 8.3.8.3. Phase Of Development, Route Of Administration, And Target Disease Indication
- 8.3.8.4. Success Protocol Analysis
- 8.3.9. Stelara® (Janssen Biotech)
- 8.3.9.1. Overview
- 8.3.9.2. Development History
- 8.3.9.3. Phase Of Development, Route Of Administration, And Target Disease Indication
- 8.3.9.4. Success Protocol Analysis
- 8.3.10. Trulicity® (Eli Lilly)
- 8.3.10.1. Overview
- 8.3.10.2. Development History
- 8.3.10.3. Phase Of Development, Route Of Administration, And Target Disease Indication
- 8.3.10.4. Success Protocol Analysis
- 8.4. Conclusion
- 9. Clinical-stage Subcutaneous Biologics: Market Landscape
- 9.1. Chapter Overview
- 9.2. Clinical-stage Subcutaneous Biologics: Overall Market Overview
- 9.2.1. Analysis By Phase Of Development
- 9.2.2. Analysis By Type Of Biologic
- 9.2.3. Analysis By Type Of Therapy
- 9.2.4. Analysis By Mechanism Of Action
- 9.2.5. Analysis By Dosing Frequency
- 9.2.6. Analysis By Drug Designation
- 9.2.7. Analysis By Target Disease Indication
- 9.2.8. Analysis By Therapeutic Area
- 9.3. Clinical-stage Subcutaneous Biologics: List Of Developers
- 9.3.1. Analysis By Year Of Establishment
- 9.3.2. Analysis By Company Size
- 9.3.3. Analysis By Location Of Headquarters
- 9.3.4. Most Active Developers: Analysis By Number Of Clinical-stage Drugs
- 10. Subcutaneous Formulation: Technology Landscape
- 10.1. Chapter Overview
- 10.2. Subcutaneous Formulation: Technology Landscape
- 10.2.1. Analysis By Fundamental Principle
- 10.2.2. Analysis By Type Of Molecule
- 10.2.3. Analysis By Route Of Administration
- 10.2.4. Analysis By Therapeutic Area
- 10.2.5. Analysis By Key Characteristics
- 10.3. Subcutaneous Formulation: Technology Developers Landscape
- 10.3.1. Analysis By Year Of Establishment
- 10.3.2. Analysis By Company Size
- 10.3.3. Analysis By Location Of Headquarters
- 11. Technology Competitiveness Analysis
- 11.1. Chapter Overview
- 11.2. Assumptions And Key Parameters
- 11.3. Methodology
- 11.4. Technology Competitiveness Analysis: Subcutaneous Formulation Technology
- 11.4.1. Subcutaneous Formulation Technology Developed By Companies Based In North America (Peer Group I)
- 11.4.2. Subcutaneous Formulation Technology Developed By Companies Based In Europe (Peer Group Ii)
- 11.4.3. Subcutaneous Formulation Technology Developed By Companies Based In Asia-pacific (Peer Group Iii)
- 12. Subcutaneous Formulation Technology Providers: Company Profiles
- 12.1. Chapter Overview
- 12.2. Technology Developers Based In North America
- 12.2.1. Cd Bioparticles
- 12.2.1.1. Company Overview
- 12.2.1.2. Technology Portfolio
- 12.2.1.3. Recent Developments And Future Outlook
- 12.2.2. Creative Biolabs
- 12.2.2.1. Company Overview
- 12.2.2.2. Technology Portfolio
- 12.2.2.3. Recent Developments And Future Outlook
- 12.2.3. Creative Biomart
- 12.2.3.1. Company Overview
- 12.2.3.2. Technology Portfolio
- 12.2.3.3. Recent Developments And Future Outlook
- 12.2.4. Pacira Biosciences
- 12.2.4.1. Company Overview
- 12.2.4.2. Financial Information
- 12.2.4.3. Technology Portfolio
- 12.2.4.4. Recent Developments And Future Outlook
- 12.2.5. The Wyss Institute
- 12.2.5.1. Company Overview
- 12.2.5.2. Technology Portfolio
- 12.2.5.3. Recent Developments And Future Outlook
- 12.2.6. Xeris Biopharma
- 12.2.6.1. Company Overview
- 12.2.6.2. Financial Information
- 12.2.6.3. Technology Portfolio
- 12.2.6.4. Recent Developments And Future Outlook
- 12.3. Technology Developers Based In Europe
- 12.3.1. Adocia
- 12.3.1.1. Company Overview
- 12.3.1.2. Financial Information
- 12.3.1.3. Technology Portfolio
- 12.3.1.4. Recent Developments And Future Outlook
- 12.3.2. Ascendis Pharma
- 12.3.2.1. Company Overview
- 12.3.2.2. Financial Information
- 12.3.2.3. Technology Portfolio
- 12.3.2.4. Recent Developments And Future Outlook
- 12.4. Technology Developers Based In Asia-pacific
- 12.4.1. Alteogen
- 12.4.1.1. Company Overview
- 12.4.1.2. Technology Portfolio
- 12.4.1.3. Recent Developments And Future Outlook
- 12.4.2. Foresee Pharmaceuticals
- 12.4.2.1. Company Overview
- 12.4.2.2. Financial Information
- 12.4.2.3. Technology Portfolio
- 12.4.2.4. Recent Developments And Future Outlook
- 13. Subcutaneous Formulation Technologies: Partnerships And Collaborations
- 13.1. Chapter Overview
- 13.2. Partnership Models
- 13.3. Partnerships And Collaborations: Subcutaneous Formulation Technology
- 13.3.1. Analysis By Year Of Partnership
- 13.3.2. Analysis By Type Of Partnership
- 13.3.3. Analysis By Year And Type Of Partnership
- 13.3.4. Analysis By Type Of Partner
- 13.3.5. Analysis By Location Of Headquarters Of Partner
- 13.3.6. Analysis By Therapeutic Area
- 13.3.7. Most Active Players: Analysis By Number Of Partnerships
- 13.4. Analysis By Geography
- 13.4.1. Intracontinental And Intercontinental Agreements
- 13.4.2. International And Local Agreements
- 14. Subcutaneous Drug Delivery Systems: Market Landscape
- 14.1. Chapter Overview
- 14.2. Types Of Subcutaneous Drug Delivery Systems
- 14.2.1. Large Volume Wearable Injectors
- 14.2.1.1. Large Volume Wearable Injectors For Non-insulin Drugs: Market Landscape
- 14.2.1.1.1. Analysis By Status Of Development
- 14.2.1.1.2. Analysis By Type Of Device
- 14.2.1.1.3. Analysis By Usability
- 14.2.1.1.4. Analysis By Type Of Dose
- 14.2.1.1.5. Analysis By Type Of Drug Container
- 14.2.1.1.6. Analysis By Mode Of Drug Filling
- 14.2.1.1.7. Analysis By Container Volume (Ml)
- 14.2.1.1.8. Analysis By Route Of Administration
- 14.2.1.1.9. Analysis By Mode Of Injection
- 14.2.1.1.10. Analysis By Mechanism Of Action / Driving Force
- 14.2.1.1.11. Analysis By Type Of Technology
- 14.2.1.1.12. Analysis By Availability Of Connectivity Feature
- 14.2.1.1.13. Analysis By Type Of Compatible Drug
- 14.2.1.1.14. Analysis By Compatibility With High Viscosity Drugs
- 14.2.1.1.15. Analysis By Therapeutic Area
- 14.2.1.1.16. Most Active Players: Analysis By Number Of Large Volume Wearable Injectors For Non-insulin Drugs
- 14.2.1.2. Large Volume Wearable Injectors For Insulin Drugs
- 14.2.1.2.1. Analysis By Status Of Development
- 14.2.1.2.2. Analysis By Type Of Device
- 14.2.1.2.3. Analysis By Usability
- 14.2.1.2.4. Analysis By Type Of Dose
- 14.2.1.2.5. Analysis By Mode Of Drug Filling
- 14.2.1.2.6. Analysis By Container Volume (Ml)
- 14.2.1.2.7. Analysis By Type Of Diabetes
- 14.2.1.2.8. Analysis By Type Of Combination Insulin
- 14.2.1.2.9. Analysis By Period Of Use (Days)
- 14.2.1.2.10. Analysis By Type Of Device Control Feature
- 14.2.1.2.11. Analysis By Availability Of Interoperable Device
- 14.2.1.2.12. Analysis By Availability Of Continuous Glucose Monitoring (Cgm) / Blood Glucose Meters (Bgm) System
- 14.2.1.2.13. Analysis By Availability Of Automatic Insulin Delivery (Aid) / Artificial Pancreas
- 14.2.1.2.14. Analysis By Type Of Automated Insulin Delivery (Aid) Feature
- 14.2.1.2.15. Analysis By Availability Of Connectivity Feature
- 14.2.1.2.16. Analysis By Waterproof Capabilities
- 14.2.1.2.17. Most Active Players: Analysis By Number Of Large Volume Wearable Injectors For Insulin Drugs
- 14.2.1.3. Large Volume Drug Device Combinations For Non-insulin Drugs: Market Landscape
- 14.2.1.3.1. Analysis By Status Of Development
- 14.2.1.3.2. Analysis By Type Of Device
- 14.2.1.3.3. Analysis By Usability
- 14.2.1.3.4. Analysis By Type Of Dose
- 14.2.1.3.5. Analysis By Type Of Drug Container
- 14.2.1.3.6. Analysis By Mode Of Drug Filling
- 14.2.1.3.7. Analysis By Container Volume (Ml)
- 14.2.1.3.8. Analysis By Route Of Administration
- 14.2.1.3.9. Analysis By Mode Of Injection
- 14.2.1.3.10. Analysis By Type Of Compatible Drug
- 14.2.1.3.11. Analysis By Mechanism Of Action / Driving Force
- 14.2.1.3.12. Analysis By Type Of Technology
- 14.2.1.3.13. Analysis By Therapeutic Area
- 14.2.1.3.14. Leading Players: Analysis By Number Of Drug Device Combinations For Non-insulin Drugs
- 14.2.2. Autoinjectors
- 14.2.2.1. Current Market Landscape
- 14.2.2.1.1. Analysis By Stage Of Development
- 14.2.2.1.2. Analysis By Usability
- 14.2.2.1.3. Analysis By Type Of Primary Drug Container
- 14.2.2.1.4. Analysis By Requirement Of Needle
- 14.2.2.1.5. Analysis By Volume Of Container
- 14.2.2.1.6. Analysis By Type Of Dose Delivered
- 14.2.2.1.7. Analysis By Route Of Administration
- 14.2.2.1.8. Analysis By Type Of Actuation Mechanism
- 14.2.2.1.9. Analysis By Type Of Feedback Mechanism
- 14.2.2.1.10. Analysis By Availability Of Connectivity Feature
- 14.2.2.1.11. Analysis By Target Indication
- 14.2.2.1.12. Analysis By Type Of Molecule Delivered
- 14.2.2.1.13. Analysis By End User
- 14.2.2.1.14. Most Active Players: Analysis By Number Of Autoinjectors
- 14.2.3. Pen Injectors
- 14.2.3.1. Current Market Landscape
- 14.2.3.1.1. Analysis By Type Of Dose
- 14.2.3.1.2. Analysis By Storage Volume / Capacity
- 14.2.3.1.3. Analysis By Usability
- 14.2.3.1.4. Most Active Players: Analysis By Number Of Devices
- 14.2.3.2. Drug Device Combination Products
- 14.2.4. Needle Free Injection System
- 14.2.4.1. Current Market Landscape
- 14.2.4.1.1. Analysis By Actuation Mechanism
- 14.2.4.1.2. Analysis By Route Of Administration
- 14.2.4.1.3. Analysis By Type Of Formulation Administered
- 14.2.4.1.4. Analysis By Type Of Drug Delivered
- 14.2.4.1.5. Analysis By Therapeutic Area
- 14.2.4.1.6. Analysis By Usability
- 14.2.4.1.7. Analysis By Type Of Formulation Administered And Actuation Mechanism
- 14.2.5. Novel Drug Reconstitution Delivery Systems
- 14.2.5.1. Current Market Landscape
- 14.2.5.1.1. Analysis By Type Of Device
- 14.2.5.1.2. Analysis By Type Of Chamber
- 14.2.5.1.3. Analysis By Type Of Device And Type Of Chamber
- 14.2.5.1.4. Analysis By Physical State Of Drug
- 14.2.5.1.5. Analysis By Container Fabrication Material
- 14.2.5.1.6. Analysis By Volume Of Container
- 14.2.5.1.7. Analysis By Drug Class
- 14.2.5.1.8. Analysis By Device Usability
- 14.2.5.1.9. Analysis By Container Fabrication Material And Device Usability
- 14.2.5.1.10. Analysis By Type Of Pre-sterilized Devices
- 14.2.5.1.11. Analysis By Type Of User-sterilized Devices
- 14.2.5.1.12. Analysis By Type Of Sterilization Equipment Used
- 14.2.5.1.13. Most Active Players: Analysis By Number Of Novel Drug Reconstitution Systems Manufactured
- 14.2.6. Prefilled Syringes
- 14.2.6.1. Current Market Landscape
- 14.2.6.1.1. Analysis By Type Of Barrel Fabrication Material
- 14.2.6.1.2. Analysis By Number Of Barrel Chambers
- 14.2.6.1.3. Analysis By Type Of Needle System
- 14.2.6.1.4. Analysis By Volume Of Syringe
- 14.2.6.1.5. Most Active Players: Analysis By Number Of Prefilled Syringes
- 14.2.6.2. Drug Device Combination Products
- 14.2.7. Implants
- 14.2.7.1. Current Market Landscape
- 14.2.7.1.1. Analysis By Phase Of Development
- 14.2.7.1.2. Analysis By Therapeutic Area
- 14.2.7.1.3. Analysis By Implant Material
- 14.2.7.1.4. Analysis By Treatment Duration
- 14.2.7.1.5. Analysis By Type Of Delivery System
- 14.2.7.1.6. Most Active Players: Analysis By Number Of Implants
- 14.2.7.2. Subcutaneous Implants Eluting Small Molecules
- 15. Subcutaneous Drug Delivery Systems: Product Competitiveness Analysis
- 15.1. Chapter Overview
- 15.2. Large Volume Wearable Injectors
- 15.2.1. Assumptions And Key Parameters
- 15.2.2. Methodology
- 15.2.3. Product Competitiveness Analysis: Large Volume Wearable Injectors For Non-insulin Drugs
- 15.2.3.1. Products Developed By Players In North America
- 15.2.3.2. Products Developed By Players In Europe
- 15.2.3.3. Products Developed By Players In Asia And Middle East And North Africa
- 15.2.4. Product Competitiveness Analysis: Large Volume Wearable Injectors For Insulin Drugs
- 15.2.4.1. Products Developed By Players In North America
- 15.2.4.2. Products Developed By Players In Europe
- 15.2.4.3. Products Developed By Players In Asia And Middle East And North Africa
- 15.2.5. Product Competitiveness Analysis: Large Volume Drug Device Combinations For Non-insulin Drugs
- 15.2.5.1. Products Developed By Players In North America
- 15.2.5.2. Products Developed By Players In Europe
- 15.2.5.3. Products Developed By Players In Middle East And North Africa
- 15.3. Autoinjectors
- 15.3.1. Assumptions And Key Parameters
- 15.3.2. Methodology
- 15.3.3. Product Competitiveness Analysis: Autoinjectors
- 15.3.3.1. Disposable Autoinjectors
- 15.3.3.2. Reusable Autoinjectors
- 15.4. Needle-free Injection Systems
- 15.4.1. Assumptions And Key Parameters
- 15.4.2. Methodology
- 15.4.3. Product Competitiveness Analysis: Needle-free Injection Systems
- 15.4.3.1. Spring-based Needle-free Injection Systems
- 15.4.3.2. Gas-powered Needle-free Injection Systems
- 15.4.3.3. Other Needle-free Injection Systems
- 15.5. Prefilled Syringes
- 15.5.1. Assumptions And Key Parameters
- 15.5.2. Methodology
- 15.5.3. Product Competitiveness Analysis: Prefilled Syringes
- 15.5.3.1. Glass Barrel Prefilled Syringes
- 15.5.3.2. Plastic Barrel Prefilled Syringes
- 16. Swot Analysis
- 16.1. Chapter Overview
- 16.2. Comparison Of Swot Factors
- 16.2.1. Strengths
- 16.2.2. Weaknesses
- 16.2.3. Opportunities
- 16.2.4. Threats
- 17. Global Approved Subcutaneous Biologics Market
- 17.1. Chapter Overview
- 17.2. Key Assumptions And Methodology
- 17.3. Global Approved Subcutaneous Biologics Market, Till 2035
- 17.3.1. Roots Analysis Perspective On Market Growth
- 17.3.2. Scenario Analysis
- 17.3.2.1. Conservative Scenario
- 17.3.2.2. Optimistic Scenario
- 17.4. Key Market Segmentations
- 18. Approved Subcutaneous Biologics Market, By Type Of Biologic
- 18.1. Chapter Overview
- 18.2. Key Assumptions And Methodology
- 18.3. Approved Subcutaneous Biologics Market: Distribution By Type Of Biologic, Current Year And 2035
- 18.3.1. Approved Subcutaneous Biologics Market For Antibodies, Till 2035
- 18.3.2. Approved Subcutaneous Biologics Market For Proteins, Till 2035
- 18.3.3. Approved Subcutaneous Biologics Market For Nucleotides, Till 2035
- 18.4. Data Triangulation And Validation
- 19. Approved Subcutaneous Biologics Market, By Type Of Therapy
- 19.1. Chapter Overview
- 19.2. Key Assumptions And Methodology
- 19.3. Approved Subcutaneous Biologics Market: Distribution By Type Of Therapy, Current Year And 2035
- 19.3.1. Approved Subcutaneous Biologics Market For Monotherapy, Till 2035
- 19.3.2. Approved Subcutaneous Biologics Market For Combination Therapy, Till 2035
- 19.3.3. Approved Subcutaneous Biologics Market For Both Monotherapy And Combination Therapies, Till 2035
- 19.4. Data Triangulation And Validation
- 20. Approved Subcutaneous Biologics Market, By Method Of Administration
- 20.1. Chapter Overview
- 20.2. Key Assumptions And Methodology
- 20.3. Approved Subcutaneous Biologics Market: Distribution By Method Of Administration, Current Year And 2035
- 20.3.1. Approved Subcutaneous Biologics Market For Administration Via Injection, Till 2035
- 20.3.2. Approved Subcutaneous Biologics Market For Administration Via Infusion, Till 2035
- 20.3.3. Approved Subcutaneous Biologics Market For Administration Via Both Injection And Infusion, Till 2035
- 20.4. Data Triangulation And Validation
- 21. Approved Subcutaneous Biologics Market, By Therapeutic Area
- 21.1. Chapter Overview
- 21.2. Key Assumptions And Methodology
- 21.3. Approved Subcutaneous Biologics Market: Distribution By Therapeutic Area, Current Year And 2035
- 21.3.1. Approved Subcutaneous Biologics Market For Autoimmune Disorders, Till 2035
- 21.3.2. Approved Subcutaneous Biologics Market For Metabolic Disorders, Till 2035
- 21.3.3. Approved Subcutaneous Biologics Market For Oncological Disorders, Till 2035
- 21.3.4. Approved Subcutaneous Biologics Market For Hematological Disorders, Till 2035
- 21.3.5. Approved Subcutaneous Biologics Market For Inflammatory Disorders, Till 2035
- 21.3.6. Approved Subcutaneous Biologics Market For Neurological Disorders, Till 2035
- 21.3.7. Approved Subcutaneous Biologics Market For Bone Disorders, Till 2035
- 21.3.8. Approved Subcutaneous Biologics Market For Other Disorders, Till 2035
- 21.4. Data Triangulation And Validation
- 22. Approved Subcutaneous Biologics Market, By Geographical Regions
- 22.1. Chapter Overview
- 22.2. Key Assumptions And Methodology
- 22.3. Approved Subcutaneous Biologics Market: Distribution By Geographical Regions, Current Year And 2035
- 22.3.1. Approved Subcutaneous Biologics Market In North America, Till 2035
- 22.3.2. Approved Subcutaneous Biologics Market In Europe, Till 2035
- 22.3.3. Approved Subcutaneous Biologics Market In Asia-pacific, Till 2035
- 22.3.4. Approved Subcutaneous Biologics Market In Middle East And North Africa, Till 2035
- 22.3.5. Approved Subcutaneous Biologics Market In Latin America, Till 2035
- 22.4. Penetration-growth (P-g) Matrix
- 22.5. Data Triangulation And Validation
- 23. Approved Subcutaneous Biologics Market, Sales Forecast Of Drugs
- 23.1. Chapter Overview
- 23.2. Key Assumptions And Methodology
- 23.3. Drug-wise Sales Forecast
- 23.3.1. Actemra® / Roactemra®
- 23.3.2. Acthar® Gel / Acthar
- 23.3.3. Aimovig®
- 23.3.4. Ajovy®
- 23.3.5. Amvuttra®
- 23.3.6. Aranesp® / Nesp®
- 23.3.7. Basaglar® / Abasaglar
- 23.3.8. Benlysta®
- 23.3.9. Betaseron® / Betaferon® / Extavia®
- 23.3.10. Cablivi®
- 23.3.11. Cimzia®
- 23.3.12. Cosentyx®
- 23.3.13. Crysvita®
- 23.3.14. Darzalex Faspro® / Darzalex® Sc
- 23.3.15. Dupixent®
- 23.3.16. Emgality®
- 23.3.17. Enbrel®
- 23.3.18. Enspryng®
- 23.3.19. Entyvio®
- 23.3.20. Epogen® / Procrit® / Eprex®
- 23.3.21. Evenity®
- 23.3.22. Fasenra®
- 23.3.23. Fiasp®
- 23.3.24. Forteo® / Forsteo®
- 23.3.25. Gattex® / Revestive®
- 23.3.26. Genotropin®
- 23.3.27. Givlaari®
- 23.3.28. G-lasta® / Peglasta® / Neulasta® / Gran®
- 23.3.29. Gonal-f®
- 23.3.30. Haegarda®
- 23.3.31. Hemlibra®
- 23.3.32. Herceptin® Sc / Herceptin™ Hylecta
- 23.3.33. Hizentra®
- 23.3.34. Humalog®
- 23.3.35. Humira®
- 23.3.36. Humulin®
- 23.3.37. Ilaris®
- 23.3.38. Kesimpta®
- 23.3.39. Kevzara®
- 23.3.40. Kineret®
- 23.3.41. Lantus®
- 23.3.42. Leqvio®
- 23.3.43. Mircera®
- 23.3.44. Mounjaro®
- 23.3.45. Nplate®
- 23.3.46. Nucala®
- 23.3.47. Orencia®
- 23.3.48. Oxlumo®
- 23.3.49. Palynziq®
- 23.3.50. Phesgo®
- 23.3.51. Plegridy®
- 23.3.52. Praluent®
- 23.3.53. Prolia® / Pralia®
- 23.3.54. Rebif®
- 23.3.55. Reblozyl®
- 23.3.56. Rekovelle®
- 23.3.57. Repatha®
- 23.3.58. Rituxan Hycela® / Mabthera® Sc
- 23.3.59. Ryzodeg® 70/30 Sc
- 23.3.60. Saizen®
- 23.3.61. Saxenda®
- 23.3.62. Simponi®
- 23.3.63. Skyrizi®
- 23.3.64. Soliqua® 100/33
- 23.3.65. Stelara®
- 23.3.66. Strensiq®
- 23.3.67. Takhzyro®
- 23.3.68. Taltz®
- 23.3.69. Tecentriq®
- 23.3.70. Tegsedi®
- 23.3.71. Tezspire®
- 23.3.72. Toujeo®
- 23.3.73. Tremfya®
- 23.3.74. Tresiba®
- 23.3.75. Trulicity®
- 23.3.76. Tysabri®
- 23.3.77. Ultomiris®
- 23.3.78. Victoza®
- 23.3.79. Voxzogo®
- 23.3.80. Vyvgart® Hytrulo
- 23.3.81. Wainua™
- 23.3.82. Xgeva® / Ranmark®
- 23.3.83. Xolair®
- 23.3.84. Xultophy®
- 23.3.85. Zepbound®
- 24. Approved Subcutaneous Biologics Market, By Leading Players
- 25. Global Subcutaneous Biologics Formulation Technologies Market
- 25.1. Chapter Overview
- 25.2. Key Assumptions And Methodology
- 25.3. Global Subcutaneous Biologics Formulation Technologies Market, Till 2035
- 25.3.1. Roots Analysis Perspective On Market Growth
- 25.3.2. Scenario Analysis
- 25.3.2.1. Conservative Scenario
- 25.3.2.2. Optimistic Scenario
- 25.4. Key Market Segmentations
- 26. Subcutaneous Biologics Formulation Technologies Market, By Fundamental Principle
- 26.1. Chapter Overview
- 26.2. Key Assumptions And Methodology
- 26.3. Subcutaneous Biologics Formulation Technologies Market: Distribution By Fundamental Principle, Current Year And 2035
- 26.3.1. Subcutaneous Biologics Formulation Technologies Market For Encapsulation Principle, Till 2035
- 26.3.2. Subcutaneous Biologics Formulation Technologies Market For Complex Formation Principle, Till 2035
- 26.3.3. Subcutaneous Biologics Formulation Technologies Market For Conjugation Principle, Till 2035
- 26.3.4. Subcutaneous Biologics Formulation Technologies Market For Amino Acid Interaction Principle, Till 2035
- 26.3.5. Subcutaneous Biologics Formulation Technologies Market For Other Principles, Till 2035
- 26.4. Data Triangulation And Validation
- 27. Subcutaneous Biologics Formulation Technologies Market, By End User
- 27.1. Chapter Overview
- 27.2. Key Assumptions And Methodology
- 27.3. Subcutaneous Biologics Formulation Technologies Market: Distribution By Type Of End User, Current Year And 2035
- 27.3.1. Subcutaneous Biologics Formulation Technologies For Pharmaceutical And Biopharmaceutical Companies, Till 2035
- 27.3.2. Subcutaneous Biologics Formulation Technologies For Biotechnology Companies, Till 2035
- 27.3.3. Subcutaneous Biologics Formulation Technologies For Medtech Companies, Till 2035
- 27.3.4. Subcutaneous Biologics Formulation Technologies For Contract Drug Manufacturing Organizations, Till 2035
- 27.3.5. Subcutaneous Biologics Formulation Technologies For Educational Institutes, Till 2035
- 27.3.6. Subcutaneous Biologics Formulation Technologies For Medical Equipment Manufacturers, Till 2035
- 27.3.7. Subcutaneous Biologics Formulation Technologies For Other End Users, Till 2035
- 27.4. Data Triangulation And Validation
- 28. Subcutaneous Biologics Formulation Technologies Market, By Therapeutic Area
- 28.1. Chapter Overview
- 28.2. Key Assumptions And Methodology
- 28.3. Subcutaneous Biologics Formulation Technologies Market: Distribution By Therapeutic Area, Current Year And 2035
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
